Atezolizumab combined with venetoclax and obinutuzumab for frontline CLL

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=Xppbk8unJK8

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of combining atezolizumab, a humanized monoclonal a...

Speaker: Nitin Jain, Institution: The University of Texas MD Anderson Cancer Center, Event: ASH 2024, Format: Interview, Subject: Leukemia, Subject: Chronic lymphocytic leukemia, Field: Treatment, Field: Immuno-oncology, Field: Trial Updates, Medicines: Antibodies, Medicines: Atezolizumab, Medicines: Venetoclax, Medicines: Obinutuzumab, Medicines: Nivolumab, Medicines: Ibrutinib, Medicines: Pembrolizumab, NCT02846623, combination therapy, immune toxicity, MRD negativity, CLL
#############################